WonderBiotics Probiotic Strain Library
Lab of Biotics — Clinical Evidence Behind Every Formula
Explore the clinically studied probiotic strains behind WonderBiotics formulas, and see how each strain supports metabolism, digestion, immune balance, and women's health.
Bifidobacterium animalis subsp. lactis B420
Best for weight management, waist support, and metabolic health
Bifidobacterium animalis subsp. lactis HN019
Best for gut transit, bloating, and digestive comfort
Lactobacillus acidophilus NCFM
Best for digestive comfort, lactose digestion, and bloating support
Lacticaseibacillus rhamnosus GG
Best for gut barrier and immune support
Lacticaseibacillus rhamnosus HN001
Best for women's health, immune balance, and microbiome support
Lactobacillus acidophilus La-14
Best for vaginal microbiome and pH balance
The six strains above are the named organisms we build on. Below, the same evidence is re-cut by formula — what one serving actually contains, how much of it, and which published study that amount comes from.
Explore by formula
What is in the serving—and which evidence matches
Compare each formula’s core ingredients with human-studied amounts, evidence level, consumer-relevant findings, and the original published research.
How to read this table. Strain RCT = named-strain human trial. Combination RCT = named strains researched together. Human crossover = randomized absorption study. Meta-analysis = pooled randomized trials. Clinical-dose match = the per-serving or label-directed daily amount meets a human-studied dose or evidence range.
Probiotics for Weight Management
20 billion CFU at expiration · 1 capsule dailyCore, dose-transparent support for appetite, waist management, digestion, and metabolic health
Strain- and ingredient-level evidence. No finished-product clinical trial.
| Consumer benefit | Core ingredient | Evidence level | Human-studied dose | Formula amount | What the study found | Study |
|---|---|---|---|---|---|---|
| Helps manage appetite, waist size, and abdominal body fat over time | B. lactis B420™ | Strain RCT | 10 billion CFU/day 6 months · 225 adults | 10 billion CFU/day Clinical-dose match | In a six-month randomized trial, protocol-compliant participants receiving B420 reported significantly lower energy intake than placebo, with supportive waist, trunk-fat, and abdominal-fat outcomes. The prespecified primary endpoint was not statistically significant in the full intention-to-treat population, so these findings are presented as protocol-compliant analyses. | Stenman 2016 PMID 27810310 |
| Supports comfortable digestion and healthy intestinal transit | B. lactis HN019™ | Strain RCT | 1.8 or 17.2 billion CFU/day 14 days · 100 adults | 2 billion CFU/day Within clinical range | Both studied doses shortened whole-gut transit time. The lower-dose group also reported improvement across multiple tracked digestive-comfort symptoms. | Waller 2011 PMID 21663486 |
| Provides a human-studied, efficiently absorbed form of berberine for daily metabolic support | Dihydroberberine | Human crossover | 100 or 200 mg/dose Randomized crossover pilot | 100 mg/serving Clinical dose studied | In a randomized human absorption study, 100 mg dihydroberberine produced significantly greater plasma berberine exposure than 500 mg standard berberine. | Moon 2021 PMID 35010998 |
Formula context: B420, HN019, and dihydroberberine each have named human research, and each formula amount aligns with an amount evaluated in people. The cited studies evaluated the individual strain or ingredient—not the finished formula.
Probiotics for Gut Health
60 billion CFU · 12 named strainsCore strain and enzyme support for regularity, transit, abdominal comfort, and food breakdown
Strain- and ingredient-level evidence. No finished-product clinical trial.
| Consumer benefit | Core ingredient | Evidence level | Human-studied dose | Formula amount | What the study found | Study |
|---|---|---|---|---|---|---|
| Supports healthy gut transit and digestive comfort | B. lactis HN019™ | Strain RCT | 1.8 or 17.2 billion CFU/day 14 days · 100 adults | 5 billion CFU/day Within clinical range | Both studied doses shortened whole-gut transit time and supported improvement across multiple functional digestive symptoms. | Waller 2011 PMID 21663486 |
| Supports abdominal comfort in people with more noticeable digestive discomfort | L. acidophilus NCFM® | Strain RCT · subgroup | 1 or 10 billion CFU/day 12 weeks · 340 completers | 1 billion CFU/day Clinical-dose match | The trial’s primary IBS severity endpoint improved similarly across probiotic and placebo groups. In a post-hoc subgroup analysis, participants who entered with moderate-to-severe abdominal pain showed greater pain-score improvement across the NCFM groups than placebo. | Lyra 2016 PMID 28082816 |
| Supports food breakdown and post-meal digestive comfort | DigeZyme® multienzyme complex | Branded ingredient RCT | 150 mg/day 60 days · 40 adults | 100 mg/serving Human-studied ingredient | In adults with functional dyspepsia, a randomized, double-blind study reported significant improvement across multiple validated indigestion and post-meal symptom scores versus placebo. | Majeed 2018 PMID 30156436 |
| Supports regular and more frequent bowel movements | B. lactis DSM15954 (BB-12®) | Strain RCT | 1 or 10 billion CFU/day 4 weeks · 1,248 adults | 10 billion CFU/day Clinical-dose match | Both the 1-billion and 10-billion CFU doses increased average bowel-movement frequency and performed similarly, with the authors reporting a ceiling effect at the 1-billion dose. The primary responder definition narrowly missed statistical significance; a stricter responder analysis favored BB-12. | Eskesen 2015 PMID 26382580 |
| Adds a well-characterized probiotic strain shown to survive passage through the human digestive tract | L. rhamnosus GG ATCC 53103 | Human strain study | 5 billion CFU/day 3 weeks · healthy adults | 1 billion CFU/day Human-studied strain | Daily LGG consumption significantly increased recovery of viable probiotic lactobacilli in fecal samples, supporting survival through the gastrointestinal tract. This row maps strain identity and does not claim a clinical-dose match. | Dommels 2009 PMID 19684171 |
Why these ingredients lead: HN019, NCFM, and DSM15954 provide named-strain human evidence at dose-relevant formula amounts; LGG adds widely recognized strain-level human research, and DigeZyme® adds branded multienzyme research for functional-dyspepsia symptom support.
Probiotics for Vaginal Health
20 billion total CFU · 6 named strainsA Lactobacillus-led women’s microbiome formula complemented by cranberry fruit extract for an easy, everyday women’s wellness routine
Combination-level evidence. No finished-product clinical trial.
| Consumer benefit | Core ingredient | Evidence level | Human-studied dose | Formula amount | What the study found | Study |
|---|---|---|---|---|---|---|
| Supports a Lactobacillus-rich vaginal microbiome, healthy pH, and intimate comfort | La-14® + HN001™ | Combination RCT | 5 billion CFU/capsule, twice daily 2 weeks · 40 healthy women | 20 billion total CFU La-14 + HN001 included Same named strains studied | In healthy women, oral use of La-14 + HN001 as part of a studied complex significantly increased vaginal L. acidophilus and L. rhamnosus levels; the organisms remained detectable one week after use stopped. The research complex also contained bovine lactoferrin, which is not included in this formula. | De Alberti 2015 PMID 25855055 |
Formula context: La-14® and HN001™ are the evidence-mapped probiotic core, complemented by 50 mg of cranberry fruit extract per capsule. The cited strain study evaluated La-14 and HN001 as part of a research complex that also contained bovine lactoferrin; this formula does not contain bovine lactoferrin, and the research was not conducted on the finished product.
Daily Fiber Mix
5-source fiber system · 1–3 sachets dailyA flexible multi-fiber routine for regularity, fiber-gap support, and everyday fullness
Ingredient-level evidence. No finished-product clinical trial.
| Consumer benefit | Core ingredient | Evidence level | Human-studied dose | Formula amount | What the study found | Study |
|---|---|---|---|---|---|---|
| Supports daily regularity, stool volume, and more complete-feeling bowel movements | Fibersol® resistant maltodextrin | Meta-analysis of RCTs | Typically 3.8–13.5 g/day 29 randomized trials | 5 g/sachet Within clinical range | A systematic review and meta-analysis found that resistant maltodextrin significantly increased stool frequency and stool volume versus placebo and supported normal bowel function. | Watanabe 2018 PMID 29535547 |
| Supports bowel regularity with a flexible daily fiber amount that can be adjusted within label directions | 5-source fiber system Fibersol® · PHGG · polydextrose · FOS · psyllium | Fiber RCT meta-analysis | Higher-dose fiber evidence: >10 g/day 16 RCTs · 1,251 adults | 1 sachet: 5 g dietary fiber 3 sachets: 15 g dietary fiber 3-sachet amount above 10 g/day | An updated meta-analysis found that fiber supplementation improved treatment response, stool frequency, and stool consistency. Psyllium—one of this formula’s five fiber sources—was among the fiber types driving positive outcomes. Benefits were more apparent above 10 g/day and with at least four weeks of use; higher-dose fiber groups also reported more flatulence, supporting gradual intake adjustment. | van der Schoot 2022 PMID 35816465 |
| Supports fullness as part of a fiber-forward daily routine | Soluble-fiber blend five complementary fiber sources | Soluble-fiber meta-analysis | Dose and response varied by fiber type randomized controlled trials | 5–15 g dietary fiber/day Label-directed daily range | A systematic review of randomized trials found that some soluble fibers supported satiety and food-intake responses, with effects depending on fiber type, physical properties, dose, and food format. The authors rated risk of bias as high across the included studies, so this is category-level supportive evidence rather than a finished-formula outcome. | Salleh 2019 PMID 30621363 |
Daily serving context: Each sachet provides 5 g of dietary fiber from five complementary sources. Label-directed use of 1–3 sachets provides 5–15 g of dietary fiber per day. Increase intake gradually and consume with adequate fluid.
Standards
Testing & quality, built to withstand scrutiny
A multi-layer quality file, not a single certificate — WonderBiotics quality is documented across facility certification, FDA facility registration, finished-product COA, potency verification, heavy-metal screening, microbiology screening, allergen testing, and targeted adulterant analysis.
Facility & manufacturing standards
Potency verification
Safety & purity screening
Quality standard meets science standard — the same page that shows named strains and human evidence also shows manufacturing controls and finished-product verification, so customers are not asked to trust a story without a paper trail. The result: human-evidence strains, U.S. GMP-audited manufacturing, independent potency confirmation, and a documented safety screen across purity, allergens, microbiology, heavy metals, and adulterants.
Every evidence summary identifies the named strain or ingredient, the formula amount, the studied amount, the evidence scope, and the original publication. Quality statements are based on the supplied SGS, NSF/ANSI, and FDA registration documents. Statements use “supports / studied for” and make no disease-treatment or guaranteed weight-loss claims.
These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
